沙利度胺联合吉非替尼对晚期非小细胞肺癌患者生存质量及生存期的影响

摘要

目的 探讨沙利度胺联合吉非替尼靶向治疗非小细胞肺癌对患者生存质量和生存期的影响.方法 选取非小细胞肺癌患者90例,根据治疗的方案不同分为观察组和对照组患者,观察组患者采用沙利度胺联合吉非替尼治疗,对照组患者单独采用吉非替尼治疗,对比2组患者化疗缓解率、生存质量及生存期.结果 观察组患者治疗有效率为55.6%,与对照组的33.3%比较,差异有统计学意义(P<0.05),观察组患者生存质量一般健康(general health,GH)、生理功能(physical functioning,PF)、生理智能(role–physical,RP)、情感职能(role-emotional,RE)、精神健康(mental health,MH)、社会功能(social functioning,SF)、躯体疼痛(bodily pain,BP)、生命力(vitality,VT)评分明显优于对照组(P<0.05),观察组患者1、2、3、4年生存率与对照组比较差异无统计学意义,而观察组5年生存率较对照组高(P<0.05).结论 沙利度胺联合吉非替尼靶向治疗有助于改善非小细胞肺癌生存质量及5年生存率.%Objective To investigate the effect of thalidomide combined with targeted therapy of gefitinib on quality of life and survival in patients with advanced non-small cell lung cancer. Methods 90 cases with non-small cell lung cancer were selected in our hospital, according to the treatment were divided into observation group and control group, the observation group were treated by thalidomide combined with gefitinib treatment, patients in the control group received only gefitinib treatment, treatment effects was compared between the two groups, the remission rate, quality of life and survival were compared between two groups of patients. Results The effective rate of the observation group patients was 55.6%, compared with 33.3% in the control group, the difference was statistically significant (P<0.05), the life quality of the observation group of general health (general health, GH), physical functioning (PF), role –physical (RP), role-emotional (RE), mental health (MH), social functioning (SF), bodily pain (BP) and vitality (VT) were significantly better than the control group (P<0.05), there was no significant difference in 1, 2, 3, 4 years survival rate between two groups, while 5 years survival rate in observation group was higher than the control group(P<0.05). Conclusion Thalidomide combined with gefitinib targeted therapy is helpful to improve the quality of life and 5 years survival rate of non-small cell lung cancer.